Promising combo tackles rare lymphoma in early trial

NCT ID NCT04433156

Completed Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of drugs called VR-CAP (bortezomib, rituximab, and chemotherapy) as a first treatment for people with marginal zone lymphoma, a rare blood cancer. 26 patients received up to 6 cycles of treatment. Researchers measured how long patients lived without the cancer getting worse and how many responded to treatment. The study is complete, but results are not yet widely reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VR-CAP (bortezomib, rituximab, cyclophosphamide, epirubicin, prednisone)
What this could lead to: If successful, this could offer a new first-line treatment option for marginal zone lymphoma, potentially improving disease control and survival.
What could go wrong: This is a small, early-phase trial with only 26 participants and no comparison group. Results may not apply to all patients, and side effects from chemotherapy and targeted drugs can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university

Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.